Coinpaper
2025-09-15 14:13:31

Helius Medical Bets Big on Solana with $500 Million Investment

Key Highlights Helius Medical invests $500M+ to make Solana a reserve asset Forward Industries buys $1.58B in Solana at $232 per coin Solana could surge to $250 by end of 2025, says analyst Helius Medical Technologies has launched a treasury strategy centered on Solana, planning to hold the cryptocurrency as a reserve using over $500 million raised through a private equity round targeting public equities. This move highlights growing institutional confidence in blockchain assets. Strategic Investments and Funding Partners Under the offering, investors received common shares or pre-funded warrants priced at $6,881 each, set to expire three years from issuance. If fully exercised, the transaction could exceed $750 million in total value. The funding round was led by Pantera Capital and Summer Capital, with additional participation from Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic Digital. Following the deal’s expected close on September 18, 2025, Helius Medical plans to: Build an initial position in Solana and scale over 12–24 months Utilize ATM programs and other capital vehicles to deploy assets Explore staking, lending, and other DeFi instruments within Solana Maintain a conservative approach to risk management Forward Industries Makes a Massive Solana Bet Meanwhile, Forward Industries acquired 6.82 million SOL for roughly $1.58 billion, at an average price of $232 per coin, through open market and on-chain transactions. The press release noted this is the first time capital from a private equity round has been used to invest in public equity, with the round led by Galaxy Digital, Jump Crypto, and Multicoin Capital. MEXC Research chief analyst Sean Young predicts Solana could rise to $250 by the end of 2025, indicating strong optimism in the crypto market.

Get Crypto Newsletter
Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.